FDA Approves Piqray (alpelisib) as First PI3K Inhibitor for Breast Cancer
May 24, 2019 -- Today, the U.S. Food and Drug Administration approved Piqray (alpelisib) tablets, to be used in combination with the FDA-approved endocrine therapy fulvestrant, to treat postmenopausal women, and men, with hormone receptor...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Drugs & Pharmacology | Endocrine Therapy | Food and Drug Administration (FDA) | Hormones | Women